Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE068V01023
Sector:
Healthcare
Symbol:
GLAND
Gland Pharma Limited
₹1,555.00
₹-24.10
(-1.53%)
▼
Prev. Close
₹1,579.10
Open
₹1,585.00
Close
₹1,554.85
Range
₹1,477.25 - ₹1,632.75
High
₹1,595.00
Low
₹1,545.75
Ind. Close
₹0.00
VWAP
₹1,561.38
The current stock price of Gland Pharma Limited is ₹1,555.00, with a target price range between ₹1,477.25 and ₹1,632.75. The stock has experienced a price change of ₹-24.10 (-1.53%), reflecting recent market volatility.
Today's opening price was ₹1,585.00, while the previous close stood at ₹1,579.10.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Gland Pharma Limited Price Chart
Gland Pharma Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1585
- Previous Close Price: 1579.1
- Change: 5.90%
- Total Traded Volume: 154
- Total Buy Quantity: 1,524
- Total Sell Quantity: 7,248
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,567.00 | 5.00 | 0.00 |
| 1,574.00 | 5.00 | 0.00 |
| 1,579.10 | 200.00 | 0.00 |
| 1,579.95 | 9.00 | 0.00 |
| 1,580.00 | 50.00 | 0.00 |
| 1,585.00 | 0.00 | 16.00 |
| 1,585.35 | 0.00 | 4.00 |
| 1,588.75 | 0.00 | 5.00 |
| 1,590.00 | 0.00 | 250.00 |
| 1,594.10 | 0.00 | 5.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1524
Total Sell Quantity: 7248
Shareholding Patterns of Gland Pharma Limited
Key Trade Statistics of Gland Pharma Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.41 |
| Traded Value (₹ Cr.) | 22.05 |
| Total Market Cap (₹ Cr.) | 25,619.62 |
| Free Float Market Cap (₹ Cr.) | 12,340.49 |
| Impact cost | 0.05 |
| Quantity Traded | 141,236.00 |
| Deliverable Quantity | 70,555.00 |
| % of Quantity to Traded | 49.96 |
| Security VaR | 14.5 |
| Index VaR | N/A |
| VaR Margin | 14.5 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 18 |
| Face Value | 1 |
Key Price Statistics of Gland Pharma Limited
The 52-week high for Gland Pharma Limited was ₹2,220.95, recorded on 06-Aug-2024. On the other hand, the 52-week low stands at ₹1,411.10, with the lowest value recorded on 12-Feb-2025.
The upper band for trading is ₹1,894.90, and the lower band is ₹1,263.30. The price band is 20%.
The stock's daily volatility stands at 2.26, while the annualized volatility is 43.18. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (06-Aug-2024) | 2,220.95 |
| 52 Week Low (12-Feb-2025) | 1,411.10 |
| Upper Band | 1,894.90 |
| Lower Band | 1,263.30 |
| Price Band (%) | 20 |
| Daily Volatility | 2.26 |
| Annualised Volatility | 43.18 |
| Tick Size | 0.05 |
Key Securities Statistics of Gland Pharma Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 20-Nov-2020 |
| Adjusted P/E | 36.37 |
| Symbol P/E | 36.37 |
| Index | NIFTY MNC |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Gland Pharma Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Gland Pharma Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 11-Mar-2025 |
| Shareholders meeting | 11-Mar-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 10-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 10-Mar-2025 |
| Appointment | 10-Mar-2025 |
| Copy of Newspaper Publication | 01-Mar-2025 |
| Notice Of Shareholders Meetings-XBRL | 28-Feb-2025 |
| Shareholders meeting | 28-Feb-2025 |
Corporate Actions of Gland Pharma Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Annual General Meeting/Dividend - Rs 20 Per Share | 16-Aug-2024 |
| 1 | Annual General Meeting | 06-Aug-2021 |
Board Meetings of Gland Pharma Limited
Financial Results of Gland Pharma Limited
Company Directory of Gland Pharma Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Registered Office | SY.NO. 143-148, 150 and 151, Gandimaisamma X Roads D.P. Pally, Dundigal-Gandimaisamma Mandal Medchal- Malkajgiri district | HYDERABAD |
| N/A | Transfer Agent | C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West) Mumbai | MUMBAI |
Insider Trading of Gland Pharma Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | S SRINIVASA RAO | 1517600 | Buy |
| 7(2) | BH LENIN KUMAR RAJA | 2531000 | Sell |
| 7(2) | P B Ravindra Varma | 3529500 | Sell |
| 7(2) | RONG WU | 10360568 | Sell |
| 7(2) | S SRINIVASA RAO | 3533946 | Sell |
| 7(2) | P B Ravindra Varma | 3649840 | Sell |
| 7(2) | RONG WU | 11252809 | Sell |
| 7(2) | S SRINIVASA RAO | 1822000 | Sell |
| 7(2) | BH LENIN KUMAR RAJA | 5472000 | Sell |
| 7(2) | A. JAYATHEERTHA | 1766600 | Sell |
| 7(2) | K. RAGHURAMACHANDRA RAO | 2737500 | Sell |
| 7(2) | S SRINIVASA RAO | 1825000 | Sell |
| 7(2) | P B Ravindra Varma | 7300000 | Sell |
| 7(2) | T.V. SATYANARAYANA | 4100501 | Sell |
| 7(2) | PRAKASH BALIGA | 908528 | Sell |
| 7(2) | PRAKASH BALIGA | 23729391 | Sell |
| 7(2) | FOSUN PHARMA INDUSTRIAL PTE. LTD | 17540948700 | Sell |
| 7(2) | T.V. SATYANARAYANA | 1246600 | Buy |
| 7(2) | P B Ravindra Varma | 4336000 | Buy |
| 7(2) | PRAKASH BALIGA | 7317000 | Buy |
Annual Reports of Gland Pharma Limited
| Company | From Year | To Year | Att. |
|---|---|---|---|
| Gland Pharma Limited | 2023 | 2024 | |
| Gland Pharma Limited | 2022 | 2023 | |
| Gland Pharma Limited | 2021 | 2022 | |
| Gland Pharma Limited | 2020 | 2021 |
Investor Complaints of Gland Pharma Limited
Event Calendar of Gland Pharma Limited
| Purpose | Details |
|---|---|
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results | To consider and approve the financial results for the quarter and financial year ended March 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the quarter and nine months ended December 31, 2021 |
| Financial results | Gland Pharma Limited has informed the Exchange about Board Meeting to be held on 19-May-2022 to consider financial statements for the period ended March 2022 |
| Financial results | Gland Pharma Limited has informed the Exchange about Board Meeting to be held on 20-Jul-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Gland Pharma Limited has informed the Exchange about Board Meeting to be held on 26-Oct-2022 to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2022 |
| Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Gland Pharma Limited
| Company | Period | Reg.7 | Reg.40 |
|---|---|---|---|
| Gland Pharma Limited | 31-MAR-2024 | ||
| Gland Pharma Limited | 31-MAR-2023 | ||
| Gland Pharma Limited | 31-MAR-2022 | ||
| Gland Pharma Limited | 31-MAR-2021 |
Voting Results of Gland Pharma Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MS. NAINAnLAL KIDWAI, DIN: 00017806, INDEPENDENT DIRECTOR |
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MR. |
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MR. UDO |
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MS. NAINA |
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MR.nESSAJI G VAHANVATI, DIN: 00157299, INDEPENDENT DIRECTOR |
| 09-MAR-2025 | Postal Ballot | TO CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO MR. UDOnJAHANNES VETTER, DIN: 00707474, INDEPENDENT DIRECTOR |
| 08-DEC-2024 | Postal Ballot | TO APPOINT Ms. WEI HUANG (DIN 10818586) AS A NON-EXECUTIVE NON-nINDEPENDENT DIRECTOR OF THE COMPANY |
| 30-AUG-2024 | AGM | 1 - To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2024 including the Audited Balance Sheet as at 31st March, 2024; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Reports of the Board of Directors and Auditors thereon |
| 30-AUG-2024 | AGM | 7 - To appoint Mr. Wenjie Zhang (DIN: 10727581) as a Director, liable to retire by rotation |
| 30-AUG-2024 | AGM | 5 - To not fill the vacancy caused by retirement of Mr. Yao Fang as a Director, as he did not offer himself for reappointment |
| 30-AUG-2024 | AGM | 4 - To reappoint Mr. Srinivas Sadu as a Director, liable to retire by rotation and being eligible offers himself for reappointment |
| 30-AUG-2024 | AGM | 3 - To declare the final dividend on equity shares for the financial year ended 31st March 2024 |
| 30-AUG-2024 | AGM | 2 - To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2024 including the Audited Consolidated Balance Sheet as at 31st March, 2024; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereon |
| 18-NOV-2023 | Postal Ballot | TO REAPPOINT Mr. SATYANARAYANA MURTHY CHAVALI (DIN 00142138) AS AN INDEPENDENT DIRECTOR OF THE COMPANY AND CONSIDER COMMISSION ON PROFITS AS REMUNERATION TO HIM |
| 31-AUG-2023 | AGM | 1 - To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2023 including the Audited Balance Sheet as at 31st March, 2023; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Reports of the Board of Directors and Auditors there |
| 31-AUG-2023 | AGM | 5 - To appoint M/s. Deloitte Haskins & Sells, Chartered Accountants (Firms Registration No. 008072S) as Statutory Auditors of the Company and fix their remuneration. |
| 31-AUG-2023 | AGM | 4 - To reappoint Dr. Jia Ai Zhang as a Director, liable to retire by rotation and being eligible, offers himself for reappointment. |
| 31-AUG-2023 | AGM | 3 - To reappoint Mr. Srinivas Sadu as a Director, liable to retire by rotation and being eligible, offers himself for reappointment. |
| 31-AUG-2023 | AGM | 2 - To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2023 including the Audited Consolidated Balance Sheet as at 31st March, 2023; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereon. |
| 06-MAR-2023 | Postal Ballot | TO APPROVE COMMISSION ON PROFITS AS REMUNERATION TOnMr. YIU KWAN STANLEY LAU (Mr. STANLEY Y LAU) (DIN: 08455325),nINDEPENDENT DIRECTOR |
FAQs on Gland Pharma Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.